CORT•benzinga•
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study
Summary
Corcept's ALS drug dazucorilant improved survival despite missing the main goal; ovarian cancer drug combo met its target in Phase 3.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 5, 2025 by benzinga